Department of Nursing, College of Nursing, Eulji University, Seongnam, Republic of Korea; Institute of Health Services Research, Yonsei University, Seoul, Republic of Korea.
Institute of Health Services Research, Yonsei University, Seoul, Republic of Korea; Department of Research and analysis, National Health Insurance Service Ilsan Hospital, Ilsan, Republic of Korea.
Public Health. 2018 Oct;163:128-136. doi: 10.1016/j.puhe.2018.06.009. Epub 2018 Aug 24.
This study aimed to evaluate the effect of the prospective drug utilization review (DUR) system introduced in Korea in December 2010 as a real-time method to improve patient safety, in terms of changes in prescribing practices, adverse drug events (ADEs), and ADE-related healthcare expenditure, using non-steroidal anti-inflammatory drugs (NSAIDs) and their common ADEs as a guide.
We used an interrupted time-series study design using generalized estimating equations to evaluate changes in prescription rate and ADE-related healthcare expenditure. Cox regression analysis was used to evaluate the probability of NSAID-associated ADEs.
A total of 154,585 outpatients with musculoskeletal or connective tissue disorders, without pre-existing gastric bleeding or ulcers were included in this study. The primary outcome was the level and trend change in prescription rate, drug-drug interactions, coprescribed gastro-protective drugs, and defined daily dose (DDD) of NSAIDs. The secondary outcome was the probability of ADEs and changes in ADE-related healthcare expenditure.
There was a significant trend change after introducing the DUR system in terms of drug-drug interactions (-3.6%) and coprescribed gastro-protective drugs (+0.6%). The mean DDD of NSAIDs increased by 0.2. The probability of ADEs decreased overall (-1.7%) and in the high-risk group (age ≥65 years; -9.6%); however, only the latter was significant. There was no significant trend or level change in ADE-related health expenditure.
The introduction of the DUR system was associated with more efficient prescribing, including a reduction in drug-drug interactions and an increase in the use of gastro-protective drugs. The system had a positive effect on patient outcome but was not associated with reduced ADE-related costs. Further studies are needed to evaluate the long-term effects of the DUR system in Korea.
本研究旨在评估 2010 年 12 月在韩国引入的前瞻性药物利用审查(DUR)系统的效果,该系统作为一种实时方法,以改善患者安全,使用非甾体抗炎药(NSAIDs)及其常见的不良反应(ADE)作为指导,评估处方实践、药物不良反应(ADE)和与 ADE 相关的医疗支出的变化。
我们使用广义估计方程的中断时间序列研究设计来评估处方率和与 ADE 相关的医疗支出的变化。Cox 回归分析用于评估 NSAID 相关 ADE 的概率。
本研究共纳入 154585 名患有肌肉骨骼或结缔组织疾病、无预先存在的胃出血或溃疡的门诊患者。主要结局是处方率、药物相互作用、联合使用胃保护药物和 NSAIDs 的定义日剂量(DDD)的水平和趋势变化。次要结局是 ADE 的概率和与 ADE 相关的医疗支出的变化。
引入 DUR 系统后,药物相互作用(-3.6%)和联合使用胃保护药物(+0.6%)方面出现了显著的趋势变化。NSAIDs 的平均 DDD 增加了 0.2。总的来说,ADE 的概率降低了(-1.7%),高危组(年龄≥65 岁;-9.6%)也是如此,但只有后者有统计学意义。与 ADE 相关的医疗支出没有明显的趋势或水平变化。
引入 DUR 系统与更有效的处方相关,包括减少药物相互作用和增加胃保护药物的使用。该系统对患者的结果有积极影响,但与降低与 ADE 相关的成本无关。需要进一步研究来评估韩国 DUR 系统的长期效果。